9.69
2.42%
-0.24
Aeterna Zentaris Inc. stock is currently priced at $9.69, with a 24-hour trading volume of 2,391.
It has seen a -2.42% decreased in the last 24 hours and a +396.92% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $10.08 pivot point. If it approaches the $9.67 support level, significant changes may occur.
Previous Close:
$9.93
Open:
$9.98
24h Volume:
2,391
Market Cap:
$11.76M
Revenue:
$6.86M
Net Income/Loss:
$-23.37M
P/E Ratio:
-2.0794
EPS:
-4.66
Net Cash Flow:
$-15.13M
1W Performance:
+15.77%
1M Performance:
+396.92%
6M Performance:
+389.39%
1Y Performance:
+249.19%
Aeterna Zentaris Inc. Stock (AEZS) Company Profile
Name
Aeterna Zentaris Inc.
Sector
Industry
Phone
843 900 3223
Address
315 Sigma Drive, Summerville, SC
Aeterna Zentaris Inc. Stock (AEZS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-19-17 | Reiterated | Maxim Group | Buy |
May-10-17 | Reiterated | H.C. Wainwright | Buy |
May-01-17 | Reiterated | Maxim Group | Buy |
Jan-17-17 | Reiterated | Maxim Group | Buy |
Dec-02-15 | Reiterated | H.C. Wainwright | Buy |
Nov-24-15 | Reiterated | H.C. Wainwright | Buy |
Nov-23-15 | Reiterated | Maxim Group | Buy |
Apr-14-15 | Upgrade | H.C. Wainwright | Neutral → Buy |
Nov-06-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jul-17-14 | Initiated | H.C. Wainwright | Buy |
Jan-03-13 | Upgrade | MLV & Co | Hold → Buy |
Oct-09-12 | Initiated | Maxim Group | Buy |
Apr-02-12 | Downgrade | MLV & Co | Buy → Hold |
Jun-07-11 | Initiated | Oppenheimer | Outperform |
Apr-27-11 | Reiterated | Canaccord Genuity | Speculative Buy |
Nov-29-10 | Initiated | MLV Capital | Buy |
Feb-05-09 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Jun-03-08 | Reiterated | Canaccord Adams | Buy |
Apr-14-08 | Reiterated | Canaccord Adams | Buy |
Oct-03-07 | Reiterated | Rodman & Renshaw | Mkt Outperform |
View All
Aeterna Zentaris Inc. Stock (AEZS) Latest News
Aeterna Zentaris (NASDAQ:AEZS) Now Covered by StockNews.com - Defense World
Defense World
Aeterna Zentaris Seeks Meeting Delay for Merger - TipRanks.com - TipRanks
TipRanks
Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date - GlobeNewswire
GlobeNewswire
Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date
GlobeNewswire Inc.
Aeterna Zentaris Inc. (NASDAQ:AEZS) Short Interest Update - Defense World
Defense World
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update - Yahoo Finance
Yahoo Finance
Aeterna Zentaris Inc. Stock (AEZS) Financials Data
Aeterna Zentaris Inc. (AEZS) Revenue 2024
AEZS reported a revenue (TTM) of $6.86 million for the quarter ending September 30, 2023, a +66.92% rise year-over-year.
Aeterna Zentaris Inc. (AEZS) Net Income 2024
AEZS net income (TTM) was -$23.37 million for the quarter ending September 30, 2023, a -77.44% decrease year-over-year.
Aeterna Zentaris Inc. (AEZS) Cash Flow 2024
AEZS recorded a free cash flow (TTM) of -$15.13 million for the quarter ending September 30, 2023, a -17.74% decrease year-over-year.
Aeterna Zentaris Inc. (AEZS) Earnings per Share 2024
AEZS earnings per share (TTM) was -$4.81 for the quarter ending September 30, 2023, a -75.55% decline year-over-year.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Cap:
|
Volume (24h):